Illumina ILMN
-
Top Healthcare Sector Buys And Sells In Billionaire Steven Cohen's Q1 Filing
By Ganaxi Small Cap Movers : Stamford, CT-based leading multi-strategy hedge fund SAC Capital, founded and led by legendary manager Steven Cohen, filed its latest 13-F for Q1 2012 indicating that it ended the quarter with $22.24 billion in 13-F assets, up from the $15.8 billion in 13-F assets in ...
-
New Morningstar Analyst Report for Qiagen NV
… agreement to acquire Gen-Probe, Roche's attempted takeover of Illumina --could be an impetus for other companies to pursue similar ..... trading at an EV/EBITDA near or below the implied levels for Illumina and Gen-Probe. While we view the immediate possibility as …
-
Adding Alpha Through Innovation and Imagination
… diagnoses. One such example is Illumina , which we owned earlier in the ..... recognized the huge potential of Illumina ’s advanced technology to cheaply ..... which made a take-out bid to buy Illumina . Other companies we own can …
-
6 Mid-Cap Biotechnology Stocks With Great Liquidity And Rated Buy Or Better
By ZetaKap : Are you looking for mid-sized companies that still have room to grow? Are you interested in gaining exposure to biotechnology companies and companies with high liquidity? Do you prefer stocks that analysts rate as 'Buy', or better? If so, here are some ideas to start your stock search.
-
Isis: A Pick To Win The Biotech Derby
By Jessica King Holden : The biotech sector attracts a certain type of investor, one that is often not afraid of a little educated speculation in the stock market. In horse racing, a good wager involves investigating a horse's race history, its physical attributes, its unique talents, its training
-
4 Highly Liquid Biotech Stocks With Bullish Short Trends
By Kapitall : Liquidity is a very important consideration for biotech stocks. Because many biotech firms do not generate earnings until after launching a successful drug, many have to rely on their sources of liquidity to continue operations. To illustrate, we ran a screen on the biotech industry
-
Illumina ([[ ILMN ]] +2.1%) moves up after Credit Suisse upgraded the shares to Outperform earlier today, based on improved prospects for sequential growth over the short-term, primarily from its ...
Illumina ( ILMN +2.1% ) moves up after Credit Suisse upgraded the shares to Outperform earlier today, based on improved prospects for sequential …
-
Roche's Pain May Be Merck's Gain
… Having moved past significant issues with the Avastin franchise in 2011, the company failed in its efforts to acquire Illumina ( ILMN ) and now investors have to digest the surprising Phase 3 failure of its cholesterol drug dalcetrapib. Not only does …
-
Friday's U.S. Top Gainers Have A Biotech Flavor
… the sector more exposure. Added to that, we have the talk of unsolicited bids by big pharma for the likes of Ilumina's ( ILMN ) gene sequencing ability and Human Genome Science's ( HGSI ) lupus drug Benlysta. Riding the wave of success, Friday's …
-
New Morningstar Analyst Report for Illumina , Inc.
… If this method proves to be superior, Illumina 's chemistry could get leapfrogged and render the firm's products obsolete. Illumina must continually innovate and protect ..... litigation could also negatively affect Illumina 's R&D pipeline. Illumina receives …